항간질약 시장 규모, 점유율, 성장률, 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of antiepileptic drugs (AED) Market

The global antiepileptic drugs (AED) market is witnessing steady growth due to the rising prevalence of epilepsy worldwide, increasing awareness regarding neurological disorders, and continuous advancements in drug development. According to Fortune Business Insights, the market was valued at USD 17.82 billion in 2025 and is projected to grow from USD 18.57 billion in 2026 to USD 27.57 billion by 2034, registering a CAGR of 5.10% during the forecast period (2026-2034).

North America dominated the global AED market in 2025, accounting for a 48.40% market share, supported by higher diagnosis rates, strong reimbursement policies, and frequent regulatory approvals for novel epilepsy drugs.

Market Drivers

Epilepsy is one of the most prevalent neurological disorders globally, characterized by recurrent seizures, loss of consciousness, and behavioral disturbances. According to the World Health Organization (WHO, 2023), approximately 50 million people worldwide are affected by epilepsy, with nearly 80% residing in low- and middle-income countries (LMICs). This high disease burden creates a substantial demand for effective and long-term antiepileptic therapies.

The growing prevalence of epilepsy places a significant economic burden on healthcare systems, driving governments and pharmaceutical companies to expand access to treatment. In response, market players are focusing on developing target-specific drugs with improved efficacy and reduced side effects, which is positively influencing market growth.

Impact of COVID-19

The COVID-19 pandemic negatively impacted the AED market, primarily due to reduced patient visits to neurological clinics, disruptions in drug supply chains, and limited access to healthcare services. However, from 2022 onwards, neurological consultations gradually increased, restoring prescription volumes. As a result, the market is expected to regain its pre-pandemic growth trajectory during 2026-2034.

Market Trends

Rising Focus on Third-Generation Antiepileptic Drugs

A key trend shaping the market is the growing emphasis on third-generation antiepileptic drugs, designed to address unmet clinical needs such as drug resistance and adverse effects. Patent expirations of second-generation drugs have created opportunities for pharmaceutical companies to develop both innovative therapies and generics.

For instance, Eisai Co., Ltd. has actively expanded its epilepsy portfolio by launching new formulations of Fycompa (perampanel), including an injection formulation approved in January 2024 in Japan, enhancing treatment options for patients unable to take oral medications.

Market Growth Factors

Increasing Product Approvals

Despite the availability of numerous AEDs, nearly one-third of patients experience drug resistance or intolerability, prompting manufacturers to intensify R&D activities. Regulatory bodies such as the U.S. FDA and Health Canada have been approving new therapies, encouraging innovation.

For example, in June 2023, XCOPRI (cenobamate tablets) received regulatory approval in Canada for adjunctive treatment of partial-onset seizures, supporting market expansion.

Government Support

Government investments and awareness initiatives are accelerating market growth. Public healthcare expenditure on epilepsy management, as seen in countries like Australia, India, and China, is improving patient access to medications and driving adoption of AEDs globally.

Restraining Factors

Drug Supply Shortages

One of the major challenges restraining market growth is the shortage of antiepileptic drugs, particularly in Europe. Brexit-related uncertainties in the U.K. and mandatory drug reserve discussions in Switzerland have disrupted supply chains. Medicine stockpiling and limited availability can negatively affect treatment continuity, thereby restraining market expansion.

Segmentation Analysis

By Drug Generation

• Second-generation drugs dominated the market in 2026, accounting for 39.87% share, driven by blockbuster drugs such as Lyrica and Keppra.
• First-generation drugs maintained a notable presence due to affordability and long-term clinical use.
• Third-generation drugs are expected to grow at the fastest rate due to broader therapeutic benefits and fewer adverse effects.

By Distribution Channel

• Hospital pharmacies dominated the market in 2026 with a 50.70% share, supported by advanced infrastructure and reimbursement coverage.
• Retail and online pharmacies are expected to grow steadily due to improved accessibility and telemedicine adoption.

Regional Insights

• North America: Valued at USD 8.63 billion in 2025, driven by strong R&D investment and awareness programs. The U.S. market is projected to reach USD 7.27 billion by 2026.
• Europe: Growth supported by increasing regulatory approvals despite supply challenges.
• Asia Pacific: Fast-growing region due to rising epilepsy prevalence and improved healthcare access in China, India, and Japan.
• Latin America & Middle East & Africa: Moderate growth driven by developing healthcare infrastructure.

Competitive Landscape

The market is highly consolidated, with key players including Pfizer Inc., UCB S.A., GSK plc., Eisai Co., Ltd., and Sanofi. While Pfizer's Lyrica has historically dominated the market, patent expiry has intensified competition from generics and newer therapies.

Conclusion

The global antiepileptic drugs (AED) market is set for steady growth through 2034, supported by rising epilepsy prevalence, continuous drug innovation, and favorable regulatory frameworks. With the market expected to reach USD 27.57 billion by 2034, sustained R&D investments, government support, and improved access to treatment will be critical in addressing unmet patient needs and driving long-term market expansion.

Segmentation By Drug Generation

• First Generation
• Second Generation
• Third Generation

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Drug Generation, By Distribution Channel, and By Country)
  • U.S.
  • Canada
• Europe (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Epilepsy, By Key Countries/ Regions, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Pipeline Analysis
• 4.4. Overview of Challenges Faced in the Antiepileptic Drugs Market
• 4.5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
• 4.6. Impact of COVID-19 on the Market

5. Global Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 5.1.1. First Generation
  • 5.1.2. Second Generation
  • 5.1.3. Third Generation
• 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.2.1. Hospital Pharmacies
  • 5.2.2. Retail Pharmacies
  • 5.2.3. Online Pharmacies
• 5.3. Market Analysis, Insights and Forecast - By Region
  • 5.3.1. North America
  • 5.3.2. Europe
  • 5.3.3. Asia Pacific
  • 5.3.4. Latin America
  • 5.3.5. Middle East & Africa

6. North America Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 6.1.1. First Generation
  • 6.1.2. Second Generation
  • 6.1.3. Third Generation
• 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.2.1. Hospital Pharmacies
  • 6.2.2. Retail Pharmacies
  • 6.2.3. Online Pharmacies
• 6.3. Market Analysis, Insights and Forecast - By Country
  • 6.3.1. U.S.
  • 6.3.2. Canada

7. Europe Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 7.1.1. First Generation
  • 7.1.2. Second Generation
  • 7.1.3. Third Generation
• 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Retail Pharmacies
  • 7.2.3. Online Pharmacies
• 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.3.1. U.K.
  • 7.3.2. Germany
  • 7.3.3. France
  • 7.3.4. Italy
  • 7.3.5. Spain
  • 7.3.6. Scandinavia
  • 7.3.7. Rest of Europe

8. Asia Pacific Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 8.1.1. First Generation
  • 8.1.2. Second Generation
  • 8.1.3. Third Generation
• 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.2.1. Hospital Pharmacies
  • 8.2.2. Retail Pharmacies
  • 8.2.3. Online Pharmacies
• 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.3.1. Japan
  • 8.3.2. China
  • 8.3.3. India
  • 8.3.4. Australia
  • 8.3.5. Southeast Asia
  • 8.3.6. Rest of Asia Pacific

9. Latin America Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 9.1.1. First Generation
  • 9.1.2. Second Generation
  • 9.1.3. Third Generation
• 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.2.1. Hospital Pharmacies
  • 9.2.2. Retail Pharmacies
  • 9.2.3. Online Pharmacies
• 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.3.1. Brazil
  • 9.3.2. Mexico
  • 9.3.3. Rest of Latin America

10. Middle East & Africa Antiepileptic Drugs (AED) Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Generation
  • 10.1.1. First Generation
  • 10.1.2. Second Generation
  • 10.1.3. Third Generation
• 10.2. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.2.1. Hospital Pharmacies
  • 10.2.2. Retail Pharmacies
  • 10.2.3. Online Pharmacies
• 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.3.1. GCC
  • 10.3.2. South Africa
  • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Pfizer Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. UCB S.A.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. GSK plc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. H. Lundbeck A/S
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Eisai Co., Ltd.
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Sanofi
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Sunovion Pharmaceuticals Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Jazz Pharmaceuticals, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)